Oncolin Therapeutics, Inc.

17 articles about Oncolin Therapeutics, Inc.

• Oncolin Therapeutics, Inc. Board Not Able To Meet The Obligations Of An Early Stage Biotech Company Such As Intertech Bio

  3/6/2009

• Oncolin Therapeutics, Inc. Announces Appointment of Chair of Scientific Advisory Committee

  7/17/2008

• Oncolin Therapeutics, Inc. Announces the Discovery of a New More Effective Anti-Cancer Treatment in Experimental Brain Tumor Models

  6/30/2008

• Oncolin Therapeutics, Inc. Appoints Member of National Cancer Institute Advisory Board to its Scientific Advisory Board

  6/23/2008

• Oncolin Therapeutics, Inc. Announces Its Cancer Technology Will Be Presented at the 20th EORTC-NCI-AACR Symposium

  6/19/2008

• Oncolin Therapeutics, Inc. Signs Agreement with Leading Cancer Center

  6/10/2008

• Oncolin Therapeutics, Inc. Announces Its New 'Super Cell Blocker', ONC-127, Has Shown Effectiveness in Treating Cancer

  5/14/2008

• Oncolin Therapeutics, Inc. Announces That Dr. Randall K. Johnson Has Agreed to Join Its Scientific Advisory Board

  5/6/2008

• Oncolin Therapeutics, Inc. Announces the Addition of Dr. Sandra Silberman to Its Scientific Advisory Board

  4/17/2008

• Oncolin Therapeutics, Inc. Announces Its Lead Technology Has Shown to Be Effective in Treating Cancer in Animal Models

  4/15/2008

• Oncolin Therapeutics, Inc. Announces It Has Entered into Negotiations with a Leading Institution to Commercially Develop a Cancer Technology

  4/8/2008

• Oncolin Therapeutics, Inc. Obtains an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment

  4/2/2008

• Oncolin Therapeutics, Inc. Provides a Company Overview

  3/25/2008

• Edgeline Holdings to Add Industry Veteran to Its Scientific Advisory Board

  3/7/2008

• Edgeline Holdings Agrees to Terms for an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment

  2/27/2008

• Edgeline Holdings Announces an Agreement that Provides Enabling Technology for Its Lead Clinical Program

  2/20/2008

• Edgeline Holdings Announces a Strategic Business Change to Focus Exclusively on Biotechnology and is Changing Its Name to Oncolin Therapeutics, Inc.

  2/12/2008